GSK in out-licensing deal with Boston Pharmaceuticals

18 March 2021
glaxo_gsk_glaxosmithkline_big

UK pharma major GlaxoSmithKline (LSE: GSK) will out-license and option programs to Boston Pharmaceuticals (NYSE: BSX) under a newly-announced agreement.

Boston will become a preferred GSK partner for select pre-Phase II programs. This new agreement builds on the relationship established in 2018 with the US biopharma’s acquisition of five programs from the London-based company.

"This agreement makes strong strategic sense as it helps us assess the potential of multiple early-stage programs and focus on progressing our own internal assets"Initially, GSK will out-license and option two programs to Boston, the first being GSK3903371, a monoclonal antibody targeting the interleukin-1 receptor accessory protein, a tumor-associated antigen driving tumor growth and immunosuppression.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology